Widely read: First Page Personal Finance Stocks Ask Value Research Announcements IPO Analysis Fundwire Stockwire Newswire Learning

Mohammed Ekramul Haque

Mohammed Ekramul Haque leads equity research at Value Research, covering listed companies for Value Research Stock Advisor and Wealth Insight. His method is old-school value investing: buy solid companies with temporary problems, do not overpay, do nothing else. He has been at Value Research since 2011, having earlier reported as principal correspondent at Outlook Profit magazine.

Explore Other Categories

See All Categories

Name	Price Band (Rs)	Bidding Date
Horizon Industrial Parks	57 - 60	17-Aug-2026 to 19-Aug-2026
Lalithaa Jewellery Mart	190 - 201	17-Aug-2026 to 19-Aug-2026
ENS Enterprises	87 - 92	14-Aug-2026 to 18-Aug-2026
Technocrats Plasma Systems	125 - 132	14-Aug-2026 to 18-Aug-2026

IPO Monitor

Mohammed Ekramul Haque

Dangers of chasing the next Amazon or Tesla

The stock is up 20 per cent. Have you missed it?

The work never ends

The illusion of certainty

The better business at a worse price

Five highest-conviction ideas for 2026 and beyond

AI disruption of the Indian IT space: Real or hyped?

Top Picks

Parag Parikh's Thakkar promises single-digit cash

A global fund reopens even as others keep shutting

15%+ returns in 10 years: 9 flexi-cap funds that did it

Welcome to the New Value Research!

Resumption of existing subscriptions in international schemes of Invesco Mutual Fund

The problem with relying on AI for stockpicking

The tide turns: India-US trade deal breaks the gloom

Find a few great companies and then do less

Simple rules to help you navigate shaky markets

Sensible buys at an overheated market peak

The cost of chasing listings

When risk knocks, do nothing

Explore Other Categories

Slicing GST, spreading gains

Earnings may change with weather. Quality endures

Pharma stocks crash. We smell opportunity.

Sensex hits lifetime high. What should you do?

Five ways to protect your hard-earned money in an IPO-crazed world

Why Indian pharma API companies are on a multi-year rally